Navigation Links
Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- A large patient registry of "real world" uses for the CYPHER(R) Sirolimus-eluting Coronary Stent reported favorable safety and efficacy outcomes at two-year follow-up, according to clinical investigators at the of Cardiology's 56th Annual Scientific Session (ACC.07).

The MATRIX Registry is a prospective, single-arm study designed to evaluate the outcomes of percutaneous coronary intervention (PCI or balloon angioplasty) with the CYPHER(R) Stent in everyday medical practice out to five years. Sponsored by Cordis Corporation, the registry reports on clinical data from 1,522 consecutive patients in whom the CYPHER(R) Stent was implanted, including high percentages of complex patient populations that are not currently within the approved labeling, such as patients with diabetes (33.8 percent), or history of heart attack (33.4 percent), balloon angioplasty (44.6 percent) or bypass surgery (21 percent). Overall, 86 percent of the interventions involved a specific patient or lesion characteristic not currently within the approved labeling for the CYPHER(R) Stent, and would be considered "off-label."

"The MATRIX Registry provides invaluable information to help physicians assess the long-term safety of the CYPHER(R) Stent in 'real world' patient populations," said Principal Investigator George D. Dangas, M.D., Ph.D., Associate Professor of Medicine, The Cardiovascular Research Foundation/Columbia University Medical Center, who presented the results.

In spite of the overall patient and lesion complexity, the MATRIX Registry indicated low frequency of adverse events with the CYPHER(R) Stent throughout the two years of patient follow-up. Applying the Academic Research Consortium (ARC) definition of stent thrombosis, the investigators reported a 0.7 percent rate of definite stent thrombosis and a 1.1 percent rate of definite/probable stent thrombosis. Total mo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
3. Monitoring Patient Glucose Levels: New Advances in software make it easier
4. Managing Preanalytical Processes for Patient Safety
5. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
6. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/24/2008)...- Ortho-McNeil Neurologics, a,division of Ortho-Mc...y,that the U.S. Food and Drug Administration (FDA)...(topiramate), based on studies submitted in,respon...the use of TOPAMAX,in pediatric patients aged 1 to...ion to granting pediatric exclusivity, the FDA is ...
(Date:7/24/2008)...ncology Patient Accrual, DENVER, July 24 /PRNewsw...ganization (RMO), has contracted with five leading...site management services for their,clinical trials... The new,trials include the following disease indi...atic Breast Cancer, Metastatic Sarcoma, Chronic My...
(Date:7/23/2008)...y print edition of Clinical C... /- A Roche Diagnostics-sponsored,pil...pe natriuretic peptide,(NT-proBNP) confirms the po... in predicting the risk of cardiovascular adverse ...dal anti-inflammatory drugs of,the COX inhibitor c...
(Date:7/23/2008)...nCode BioPharmaceutics, Inc.,an emerging biopharm...t,results demonstrating the utility of their lead ... chronic blood disorder paroxysmal nocturnal,hemog...ented at the XXII,International Complement Worksho... only treatment currently available for PNH patien...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Cancer researchers seek safe reduction of radiotherapy 2663 1Cancer researchers seek safe reduction of radiotherapy 2663 2New clinical guideline for low back pain 2661 1New clinical guideline for low back pain 2661 2New clinical guideline for low back pain 2661 3Vaginal progesterone gel may improve infant outcomes and 2659 1Vaginal progesterone gel may improve infant outcomes and 2659 2Vaginal progesterone gel may improve infant outcomes and 2659 3Vaginal progesterone gel may improve infant outcomes and 2659 4Drug Combo Helps Fight Marfan Syndrome 2658 1Drug Combo Helps Fight Marfan Syndrome 2658 2
...ERYVILLE, Calif., April 16, 2007 /PRNewswire-First...e mechanism of action of,its anti-cancer agent BZL...ing for late stage breast cancer at the American,A... the Los Angeles,Convention Center in Los Angeles,...ntation will describe the pathway for,cancer cell ...
...USAND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 ...from a randomized,double-blind, placebo-controlle... of Aranesp(R) (darbepoetin alfa) for the,treatmen...eiving,chemotherapy or radiotherapy ("the 103 stud... EMEA in these patients. These,results were presen...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
...ncer, such as radiotherapy, surgery and drugs as w...edical training// vary throughout the EU, accordin... Medical Oncology (ESMO) on 3 October 2006. Access...om country to country. The survey published in Me...
...ur of daily physical exercise for their future goo...agues at Glasgow University studied 545 children a...red the children who had the recommended adult lev...s, three times a week, reported the online edition...
...al health wards have been graded as unpleasant or ...atients//. The charity called Mind revealed that ...te of repair of their ward while 28% were not sati...Mind is for patients to be treated in a therapeuti...
...erts, some cancer patients are experiencing unjust...te of the new legislation to protect their rights/...fect from the end of last year has provided effect...h severe illnesses like cancer, multiple sclerosis...
Other Medicine News:Health News:Mental Health Wards rated unpleasant 2Health News:Injustice to cancer patients at work 2
Large deep curve.
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl
Utilizing breakthrough electro-optical and rotary prism technology, the new RM-8000B SUPRA is capable of obtaining perfectly accurate refraction measurements through pupils as narrow as 2.0mm. This m
Sterile free isotonic balanced salt solution
Medicine Products: